Abstract | The combination of obesity and hypertension is associated with high morbidity and mortality because it leads to cardiovascular and kidney disease. Potential mechanisms linking obesity to hypertension include dietary factors, metabolic, endothelial and vascular dysfunction, neuroendocrine imbalances, sodium retention, glomerular hyperfiltration, proteinuria, and maladaptive immune and inflammatory responses. Visceral adipose tissue also becomes resistant to insulin and leptin and is the site of altered secretion of molecules and hormones such as adiponectin, leptin, resistin, TNF and IL-6, which exacerbate obesityassociated cardiovascular disease. Accumulating evidence also suggests that the gut microbiome is important for modulating these mechanisms. Uric acid and altered incretin or dipeptidyl peptidase 4 activity further contribute to the development of hypertension in obesity. The pathophysiology of obesity-related hypertension is especially relevant to premenopausal women with obesity and type 2 diabetes mellitus who are at high risk of developing arterial stiffness and endothelial dysfunction. In this Review we discuss the relationship between obesity and hypertension with special emphasis on potential mechanisms and therapeutic targeting that might be used in a clinical setting.
Introduction
Epidemiological data indicate that the current global obesity epidemic began approximately 40 years ago; 1 however, some studies suggest that the rise in obesity rates started earlier, and that the progression of the epidemic has been somewhat irregular. [2] [3] [4] The causes of the obesity epidemic are most frequently ascribed to two factors: the combination of institutionally driven decreases in physical activity (for example, reductions in school physical education classes and the sedentary nature of most modern vocations); and over-nutrition resulting from modern food marketing practices and technology (such as inappropriately large portion sizes in restaurants and processed foods and the ready availability of inexpensive high-calorie fast food). 4, 5 However, evidence also suggests that additional factors might contribute to the obesity epidemic, including sleep debt, endocrine disruptors and intrauterine and intergenerational effects, and these have been extensively reviewed elsewhere. 4, 6 Obesity is a major public health burden in the USA and >300,000 deaths each year are attributable to obesity or being overweight. 7, 8 In the USA, among the adult population of ~240 million individuals, >65% are overweight and, of these, half have obesity; 9 moreover, approximately 13 million US children are also estimated to have obesity. 10 Worldwide, in both developed and developing nations, one billion people are either overweight or have obesity, making this disorder a global epidemic. 11 In 1967, a prospective analysis of data from the Framingham Heart Study highlighted the relationship between obesity and hypertension. 12 Indeed, the high prevalence of hypertension among patients with obesity (>60%) accounts for 78% of incident hypertension in men and 64% of incident hypertension in women. [13] [14] [15] The prevalence of hypertension increases in relation to BMI in both men and women after adjusting for age. 16, 17 Estimates indicate that the increased risk of developing hypertension is 20-30% for every 5% increment in weight gain. 18 Even before the Framingham Heart Study data, researchers reported on the potential mechanisms of hypertension in patients with obesity by linking the cardiovascular and metabolic complications of obesity to adipose tissue that is distributed primarily at and above the waistline (that is, upper-body obesity). 19 Contemporaneous studies reported metabolic abnormalities associated with upper-body obesity, including insulin resistance and hypertriglyceridaemia. 20, 21 This concept was further refined in the 1980s when researchers demonstrated that an increase in the waist-to-hip ratio was associated with increased risk of hyper tension. [22] [23] [24] The clustering of abdominal obesity, hypertension, insulin resistance and hypertriglyceridaemia was, therefore, the key to later development of the concepts of the metabolic syndrome and cardiorenal syndrome (CRS). 25, 26 Clinical trials have, for the most part, demonstrated that weight loss of ~10% of original body weight by calorie restriction and/or increased activity is an effective means to achieve clinically meaningful reductions in blood pressure and mortality from cardiovascular disease (CVD).
Several other reviews have focused on specific factors contributing to obesity-associated hypertension. [29] [30] [31] [32] [33] [34] [35] [36] [37] In this Review, we present an integrated view of the pathophysiology of obesity-associated hypertension and discuss the relationships between the multiple factors contributing to this condition. We also discuss factors that contribute to obesity-associated hypertension, including incretin signalling, dysfunctional immunity and the gut microbiome, as well as specific antihypertensive therapies especially relevant to patients with obesity.
Obesity and hypertension
Progression from a normotensive to hypertensive phenotype results from a combination of genetic, environmental, behavioural and dietary factors (Figure 1 ). The combination of obesity and hypertension has two important consequences. Firstly, this combination is particularly insidious in that the population with obesity and hypertension have high morbidity and mortality from CVD, including coronary heart disease, congestive heart failure, sudden cardiac death, chronic kidney disease (CKD), end-stage renal disease and stroke. 29 Secondly, obesity increases the risk of treatment-resistant arterial hypertension, which therefore requires multiple medications and device therapy, such as renal sympathetic denervation. 7, 38 Conversely, in population studies, future weight gain is significantly higher in patients with hypertension than in normotensive individuals, indicating that hypertension per se contributes to the increased risk of obesity 12 and implying a further link between obesity and hypertension.
Before menopause women are protected against CVD, including hypertension, compared with age-matched men owing to the cardioprotective effect of estrogen; 39 how ever, in the setting of obesity or type 2 dia betes mel litus (T2DM) this protection is lost. [40] [41] [42] [43] Popula tion studies indicate that women who are premenopau sal but obese have a substantially higher risk of developing hyper tension (43-56%) than age-matched men with obesity (20-27%). 44 Weight loss of 5-10 kg in women with obesity substantially lowers the risk of developing Key points ■ The incidence of hypertension is substantially increased in the population of people with obesity and affected individuals have increased morbidity and mortality from cardiovascular disease (CVD) and chronic kidney disease ■ Adipokine alterations, insulin resistance, sympathetic nervous system and renin-angiotensin-aldosterone system activation, obstructive sleep apnoea, renal abnormalities, maladaptive immunity and gut microbiome changes all link hypertension to obesity ■ Hyperuricaemia associated with a high-fructose diet is emerging as a key factor in the development of hypertension associated with diet-induced obesity ■ Dysregulation of the dipeptidyl peptidase 4-incretin system contributes to the development of maladaptive immunity and associated hypertension in obesity ■ Estrogen-mediated CVD protection is compromised in individuals with obesity, thereby underscoring the greater CVD risks associated with obesity in premenopausal women compared with those in age-matched men with obesity ■ Adjunctive therapy with mineralocorticoid receptor antagonists and renal denervation is emerging as an additional therapeutic measure for management of obesity-related hypertension hypertension by up to 25%. 45, 46 Moreover, maternal and paternal obesity also seem to increase the risk of off spring to develop obesity and hypertension in early adult life. 32, 47, 48 Given the differences in cardio vascular phy siology between sexes, women might require female-specific and more aggressive therapeutic and life style management for obesity and its cardiovascular complication s than men. 41 
Dietary factors
Fructose, fat and sodium The current global obesity epidemic has primarily been ascribed to excess consumption of energy-dense foods, which are high in sugar, fat and sodium, in combination with an increasingly sedentary lifestyle. 1 The introduction of high-fructose corn syrup (HFCS) in 1967 in the USA, and its dramatic increase in consump tion compared with other carbohydrates between 1970 and 1990, has been related to obesity, CRS and diabetes mellitus. 37, 49, 50 HFCS is more lipogenic than other sugars and increases the circulating levels of triglycerides, insu lin, glu cose and LDL cholesterol, 51 factors that increase the risk of progression to the metabolic syndrome and CVD. Increased HFCS consumption is also associated with ele vated uric acid synthesis (a property that is unique among sugars 51 ) and emerging evidence supports a role for uric acid in the development of hypertension and CVD. 37, 52 However, the hypothesis that fruc tose and uric acid can induce hypertension is controver sial. For example, in rodent studies, conflicting reports sug gest that fructose consumption can lead to either no change 53 or an increase 54, 55 in blood pressure. These differ ences might be attributable to the methodology used to measure blood pressure, 53, 56 if fructose is dis solved in water (like in a sweetened beverage) or con sumed in addition to high-fat or high-salt diets. 53, 56, 57 Results reported in clinical studies are equally controversial owing to differences between study design, treatment dura tion, variability of nutrient composition or form of fructose added to the diet (for example, fructose, HFCS, sucrose, or natural fruits). 57 Investigators have pre sented consistent evidence supporting the observation that reducing sodium intake can lead to reductions in blood pressure. 58, 59 How ever, admini stering fructose with a high-salt diet leads to hyper tension that persists even after removal of fructose from the diet. 54 Similarly, mice fed with a combination of high-fructose and high-fat diet for 6 months also develop hypertension. 56 These results suggest a synergistic deleterious effect owing to the interaction of fructose with either salt or high fat content. Additional well designed prospective studies are, therefore, needed to deter mine the effect of HFCS in the development of obesity-associated hypertension. 50 
Cardioprotective nutrients
The undesirable dietary changes in the USA during the past 50 years might be further exacerbated by the imbalance in consumption of omega-6 and omega-3 fatty acids. Omega-3 fatty acids must be obtained from an individual's diet. Humans evolved on diets that contained fairly equal amounts of omega-6 and omega-3 fatty acids. However, in the past 50 years the US diet has become deficient in omega-3 fatty acid (ratio of omega-6 to omega-3 ~15:1) owing to increased consumption of plant-derived oils (soybean and corn oils) and red meat from grain-fed animals, which are rich in omega-6 but not omega-3 fatty acids. 60 Consequently, cold water marine fish have received much attention by dieticians due to their high content of omega-3 and more balanced ratio of omega-6 to omega-3 fatty acids. In metaanalyses, fish oil supple ments lower blood pressure in patients with hyper tension. 61, 62 However, the reports that fish oils can prevent CVD in general are inconclusive. 63 Combination diets, notably the Dietary Approaches to Stop Hypertension (DASH) diet, 64 which is rich in nutrients from fruits, vegetables and has modest levels of sodium, omega-3 and omega-6 fatty acids, have emerged as part of a balanced strategy for the management of hyper tension. Approaches such as the DASH diet include green leafy (for example, cabbages, spinach and lettuces) and root (carrots and beets) vegetables that are rich in inorganic nitrate. 65 Beetroot juice, which also contains high levels of inorganic nitrate, can also lower blood pressure. 66, 67 The nitrate content of these foods is likely to contribute to increased nitric oxide (NO) bioavailability, which has multiple beneficial pleiotropic effects in the vasculature such as vasodilation. 68 
Gut microbiota, obesity and hypertension
Emerging evidence suggests that changes in the gut bacterial microbiome, associated with genetic and dietary factors, can lead to metabolic disorders that result in obesity, insulin resistance, T2DM and hypertension. 69, 70 In ob/ob 71, 72 and db/db 73 mice, the number of caecal bacteria from the phylum Bacteroidetes (so called 'good bacteria') is reduced, which is accompanied by a proportional increase in the number of bacteria from the phylum Firmicutes (so called 'bad bacteria'). Bacterialderived lipopolysaccharides are thought to regulate hormones such as apelin in adipose tissue that alter glucose homeostasis and inflammation. 73 Mice fed a high-fat diet have progressive increases in the number of Firmicutes suggesting that the quality of the diet can modulate the gut microbiome. 74 Changes in the gut microbiome lead to abnormalities in pattern recognition receptor function, immune and inflammatory responses, and insulin sensi tivity. 75 These studies suggest that therapeutic manipulation of the gut microbiome (for example, by faecal transplantation or oral prebiotic or probiotic preparations) might potentially suppress immune and inflammatory responses and improve insulin sensitivity -a novel approach that might be used to manage obesity and hypertension in humans.
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Mechanisms of hypertension in obesity
The development of hypertension in patients with obe sity is dependent on the interactions between diet ary, genetic, epi genetic, and environmental factors ( Figure 1 ). 78, 79 Adipo cyte dysfunction in patients with obe sity contributes to vascular and systemic insulin resistance and the dysfunction of the sympathetic nervous system (SNS) and the renin-angiotensin-aldosterone system (RAAS). 7, 78 Structural and functional changes in the kidney, including activation of intra renal angio tensin II (Ang II), are also important in the development of ob esity-associated hypertension. 80 For example, some investigators have suggested that arterial hypertension in lean patients is Visceral adipocyte dysfunction leads directly to renal, cardiac and vascular dysfunction, via an impaired immune or inflammatory response, and by affecting neuroimmune interactions that alter SNS signalling. Cardiac and/or renal abnormalities can lead to vascular dysfunction and vice-versa. Obesity-related hypertension is associated with structural and functional changes in the kidney, heart and vasculature. Hyperuricaemia might also affect adipocyte function and vascular remodelling, and cause renal abnormalities. Abbreviations: , increased; , decreased; Ang II, angiotensin II; DPP-4, dipeptidyl peptidase 4; MCP-1, monocyte chemoattractant protein-1; PNS, parasympathetic nervous system; RAAS, renin-angiotensinaldosterone system; SNS, sympathetic nervous system; T H , T helper cell; T REG , T regulatory cell.
mediated by an increase in peripheral vascular resistance, whereas hyper tension in individuals with obesity is mediated, in part, by increased intravascular volume, cardiac output, 81 and proximal tubule sodium absorption in the kidney. 82 However, crosstalk between components of the intravascular RAAS, specifically Ang II and aldosterone, can also regulate vasoconstriction independently of renal control. 83, 84 Accumulating evidence also suggests that uric acid might affect adipocyte function, and lead to vascular and renal injury. 37, 85 Moreover, incretin signalling is also an important modulator of insulin resistance and immune function. 86 The interplay between genetic and environmental factors (that is, epigenetic mechanisms) might also contribute the pathophysiology of obesity-associated hypertension. 79, 87 Epigenetic mechanisms include changes in DNA methy lation, histone modifications and microRNA (miRNA) regulation. 88 For example, the miRNAs miR-142-3p and miR-140-5p are increased in patients with morbid obesity, and are biomarkers of the dis ease. 89, 90 Epigenetic factors are also relevant to the develop ment of obesity-related hypertension, 91, 92 and might con tribute to in utero epigenetic programming, which has been used to explain the origins of fetal and infant diseases. 93, 94 Accumulating evidence suggests that environmental factors during early life might also program the development of obesity and hypertension, but these aspects are beyond the scope of this Review. 29, 32 Vascular injury Endothelial dysfunction and arterial stiffness are thought to be the earliest manifestations of vascular dys function in obesity and precede the development of pre hypertension and hypertension (Figure 1) . [95] [96] [97] [98] Increased arterial stiffness is seen in patients who are normo tensive but have obesity and who are predisposed to develop hyper tension; moreover, incident hyper tension is more robustly predicted in patients who are in the highest quartile of ar terial stiffness. [95] [96] [97] [98] Changes in the extra cellular matrix 99 and vascular smooth muscle dysfunction 100 contribute to arterial stiffness; however, accumulating evidence suggests that endothelial dysfunction also contributes to vascular stiffness, which is in turn strongly associated with insulin resistance. 98, 101 Impaired vascular reactivity to insulin before the onset of hypertension is seen in spon taneously hypertensive rats, 102 suggesting that insu lin resis tance is an early event in hyper tension development. In the vasculature two components of insulin signal ling exist: metabolic and growth factor signalling. Meta bo lic signalling involves insulin receptor substrate-1 (IRS-1), phospho inositide 3-kinase, protein kinase B (AKT), and endothelial nitric oxide synthase (NOS); growth fac tor signal ling functions via the extracellular sig nal regu lated kinases (ERK)1/2 and en dothelin-1 (ET-1) path ways. 84, [103] [104] [105] In insulin resistant states, metabolism is impaired owing to serine phosphory lation of IRS-1, which leads to reduced NO bioavailability and impaired vas cular relaxa tion. 103 Conversely, in this state, upregulation of the ET-1 pathway contributes to increased vascular contraction. 103 The imbalance in pathway-selective insulin signalling in obesity can, therefore, contribute to en dothelial dy sfunction and arterial stiffness. In patients with obesity, metabolic changes in adipose tissue lead to altered secretion of bioactive molecules and hormones-collectively referred to as adipokines -such as angiotensinogen, aldosterone stimulating factor, dipeptidyl peptidase 4 (DPP-4), leptin, resistin, TNF and IL-6 ( Figure 1 ). These factors can contribute to o besity-associated insulin resistance and hypertension. 106 Impaired adiponectin secretion also promotes insulin resistance. 78, 107, 108 Renal injury Abnormal renal function also leads to hypertension in patients who have obesity, as well as in animal models of obesity (Figure 1) . 109 Obesity increases tubular absorption of sodium and promotes a compensatory shift in the pressure natriuresis curve towards higher blood pressure in response to elevated plasma sodium levels. 78, 110 Moreover, these effects on sodium and pressure natriuresis can be caused by an increase in adipose tissue mass and extracellular matrix accumulation, which compress the renal medulla. Hyperinsulinaemia and inappropriate RAAS and SNS activation also contribute to increased sodium resorption. 78 Renal vascular remodelling, characterized by inflammation, endothelial dysfunction and vascular smooth muscle proliferation, is seen in humans and animals with hypertension. 111 Tubulointerstitial inflammation owing to a systemic immune and inflammatory response, elevated uric acid levels, tubulointestinal infiltration of immune cells, circulating proinflammatory immune cells and enhanced inflammation, oxidative stress and fibrosis collectively contribute to renal damage. 37, 50, 78, 112 The kidney regulates plasma glucose levels by reabsorb ing almost all of the glucose filtered by the glo meruli (~162 g per day). 113 Glucose reabsorption is pri marily localized to the S1 segment of the proximal convoluted tubule and functions via high-capacity, low-affinity sodium-glucose cotransporter-2 (SGLT2). 114 In humans with diabetes mellitus, 115 Zucker diabetic fatty rats, 116 and db/db mice 117 SGLT2 expression is increased in the proximal convoluted tubule, which correlates with glomerular hyperfiltration leading to increased glucose reab sorption. 117 This increased reabsorption leads to ele vated plasma glucose levels and glucose toxicity, and sodium reabsorption, which also contributes to sodium reten tion. 118 In hypertensive rats, Ang II regulates the increase in SGLT2 expression via the angiotensin II type 1 receptor (AT 1 R), supporting a role for SGLT2-mediated sodium reabsorption in the development of hyper tension. 119, 120 Moreover, in vivo data suggest that insu lin is an agonist for this effect of SGLT2 in humans and is important for postprandial glucose and sodium reabsorption. 121 Emerging evidence also indicates that inhibition of SGLT2, with molecules such as dapagliflozin, in animal models or humans with T2DM induces a mild osmotic/ natriuretic effect that promotes modest reductions in blood pressure and body weight, which might reduce the risk of a future cardiovascular event.
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REVIEWS SNS overactivation
Obesity is associated with activation of the SNS in diverse tissues-including the heart, kidneys, and skeletal muscle-and with baroreflex dysfunction, leading to altered blood pressure. 33, 34, 125, 126 Regardless of blood pressure, individuals who are obese have increased renal SNS activity compared with healthy indivi duals, indicated by an elevation in renal norepinephrine levels. 33 Interestingly, individuals who have obesity but are normo tensive have suppressed cardiac SNS activity, whereas those who have obesity and hypertension have elevated cardiac SNS activity. 33 Increases in both renal and cardiac SNS activity might, therefore, be one mechanism that leads to the development of hyper tension in obesity. The importance of SNS activation in the kidney to obesity-related hypertension is highlighted by evidence that renal denervation can lower blood pressure and increase sodium excretion in a canine model fed on a high-fat diet. 127 However, other studies suggest that SNS activation alone might not lead to the development of hypertension. Increased α-adrenergic-mediated vascular tone has been reported in overweight men, most of whom had hypertension; 128 however, hypertension, rather than body weight, might account for the increase in SNS activity reported in this study. In individuals who have obesity but are normotensive the observed increase in sympathetic outflow to the forearm musculature does not lead to an increase in peripheral sympathetic vascular tone. 129 The authors speculated that a dissociation between SNS activity and peripheral vascular tone can protect a subset of individuals with obesity from developing hypertension, which might explain the small population of individuals with obesity but normal blood pressure. 129 However, definitive evidence that hypertension in individuals with obesity is either initiated or maintained solely by a neurogenic mechanism has yet to be determined. 130 Several factors have been suggested to promote obesity-associated hypertension by activating the SNS, including hyperinsulinaemia, hyperleptinaemia, RAAS activation (via Ang II), baroreflex dysfunction and obstruc tive sleep apnoea (OSA) (Figure 1) . 131, 132 How ever, evi dence suggests that hyperinsulinaemia itself does not promote hypertension. 133, 134 Increased leptin secretion from dysfunctional adipose tissue is also an important modulator of SNS activity. 131 Disruption of signal transducer and activator of transcription 3 (commonly known as STAT3) signalling in the arcuate nucleus leads to resistance to the anorexic effects of leptin and might result in weight gain. 135 Conversely, preservation of leptin sensitivity in the ventromedial and dorso medial hypothala mus, involving activation of PI3 kinase and melano cyte stimulating hormone and its receptors, leads to enhanced renal sympathetic outflow. 131, 132 Low adipo nectin and increased apelin levels are linked to SNS activation, although their role in SNS regulation is unclear. 108, 136 Progression to a chronic hypertensive state in individuals with obesity might be preceded by a loss of nocturnal blood pressure dipping in the absence of elevated daytime blood pressure. 137, 138 A non-dipping pattern of circadian blood pressure increases the risk of CVD and CKD. 137, 139 The exact mechanisms for this non-dipping pattern of blood pressure are unknown; however, insulin resistance, autonomic nervous system dysfunction, increased SNS activity and increased inflammation can all contribute to the phenomenon. 137, 140 OSA and hypertension are typically associated comor bidities. 50-60% of individuals with OSA are hyper tensive and half of individuals with hypertension have OSA. 141 Moreover, the frequency of the association of these comorbidities is even higher in those with treatment-resistant hypertension. 142, 143 OSA activates the SNS independently of obesity-related mechanisms 144, 145 and, therefore, might be a major factor that promotes treatment-resistant hypertension in those who have obesity. Renal sympathetic denervation has led to positive improvements in blood pressure, OSA and glycaemic control in patients with obesity and treatment-resistant hypertension.
14,38,146 OSA is also highly prevalent among individuals with treatment-resistant hypertension and elevated aldosterone levels. 146 SNS activation and aldosterone production in response to non-classical adrenal stimuli might contribute to the increased aldosterone levels seen in patients with obesity ( Figure 2) . 146, 147 Aldosterone regulates blood pressure via mineralo corti coid receptors in both the renal and vascular systems. 148 Treatment with a continuous positive airway pres sure assist device and mineralocorticoid receptor inhibitors to limit the deleterious effects of elevated aldosterone levels can reduce the severity of OSA and no rmalize blood p ressure (Figure 2) . 146 
RAAS
In patients with obesity, inappropriate activation of RAAS modulates insulin resistance, SNS activation, dysfunctional immunity and abnormal renal sodium handling, which collectively contribute to cardiovascular and renal dysfunction (Figure 1) . 40, 78, 84, 108 In addition to the conventional circulating endocrine RAAS proteins, the heart, kidney, vasculature, adipose tissue, immune cells and brain express RAAS proteins as part of a tissue-specific local effect. 98, [149] [150] [151] [152] Ang II synthesis by intravascular and intrarenal RAAS might directly regulate vascular stiffness, and endothelial and renal function. 98, 153 Ang II also modulates vascu lar and renal function by inhibiting metabolic insulin signal ling and enhancing ERK1/2 and ET-1 signalling. 84, 104 Expression of RAAS components and increased expression and secretion of angiotensinogen by adipose tissue in obesity states supports a role for local RAAS activation in adipose tissue dysfunction. 152 More over, increased Ang II production by perivascular adipose tissue contributes to impaired vascular function. 154 This concept is further supported by studies in mice with an adipocyte-specific angiotensin knockout. When fed a high-fat diet, these mice have a lower blood pressure than wild-type control mice on an identical diet. 155 Circulating aldosterone might also be involved in the development of hypertension in individuals with obesity. Obesity can be accompanied by elevated plasma aldo sterone levels 156 and soluble factors derived from adi pose tissue stimulate adrenal aldosterone secretion. [157] [158] [159] Endo thelial dysfunction 160 and enhanced vas cular smooth muscle reactivity have both been impli cated in the modulation of vascular remodelling by aldo sterone. 98 Patients with primary hyper aldo steronism can be insulin-resistant, and aldosterone levels have been corre lated with BMI and insulin resistance in patients with obesity who are normotensive. 161 The precise role of aldosterone-induced vascular insulin resis tance has not been fully elucidated; however, suppression of local inflammation and vascular stiffness by the mineralocorticoid antagonist spironolactone in rodent models of hyper tension and insulin resistance has been reported. 98, 162 Aldo sterone activates nicotinamide adenine dinucleotide phosphate-oxidase (NADPH), which promotes oxidative stress and decreases NO bioavailability. 163 Aldosterone also increases endothelial stiff ness by modulating epithelial sodium channel expression on the endothelial cell surface and NO release. 163 Spironolactone can lower blood pressure in patients with obesity with elevated plasma aldosterone levels, although insulin resistance is unchanged in these patients. 161, 164 Mineralocorticoid receptor antagonists might improve insulin resistance in patients with hyperaldostero nism in contrast to indivi duals with obesity in whom aldosterone levels are only moderately elevated. 164 How ever, insulin resistance in obesity can also develop via other pathways, including through the effects of over nutrition and SNS over activation, meaning that mineralo corticoid receptor antagonists might not be appropriate in this con text. 40, 165 In this regard, eplerenone, a drug with higher binding specificity for the mineralo corticoid receptor than spironolactone, improved flow-mediated dilation in healthy indivi duals 55-79 years old. 166 Moreover, impaired endothelial function was improved in obese mice or exogenous-aldosterone-infused lean mice with an endothelial-specific mineralo corticoid receptor deletion. 167 A subset of individuals with obesity and hypertension might also have insulin-resistancerelated hyperaldosteronism, for which mineralocorticoid receptor inhibitors might be useful to treat. 168 Attenuation of Ang II-induced vascular damage by mineralocorticoid receptor antagonists suggests a crosstalk between the Ang II and aldosterone signalling pathways. 84, 169 For example, Ang II-induced vascular smooth muscle contraction and hypertension are reduced in mice with a deletion of mineralocorticoid receptor specific to smooth muscle cells. 148 This study also suggests mineralocorticoid receptor-regulated blood pressure is indepen dent of hypertension induced by renal mechanisms. Both the direct beneficial effects of mineralocorticoid receptor antagonists, and their role in reducing Ang II-induced pathology support the adjunctive use of mineralo corticoid receptor antagonists to manage re sistant hy pertension in obesity. 29, 38 Immune and inflammatory mechanisms Accumulating evidence suggests that in patients with obesity, dysfunctional innate and adaptive immune and inflammatory responses contribute to vascular dysfunction and the pathogenesis of hypertension. However, the mechanisms and mediators of this relationship are still not well understood. Immune-mediated injury in obesity and hypertension can occur in the vasculature, central nervous system, kidney and adipose tissue, including perivascular tissue (Figure 1) . 112, 170, 171 Innate immunity Macrophage infiltration into adipose tissue is associated with systemic insulin resistance. 172 Distinct macrophage phenotypes elicit either a proinflammatory (M1 macrophages) or an anti-inflammatory res ponse (M2 ma crophages). 172 Lipid-filled foam cells are a type of acti vated M1 macrophage that secrete pro inflam matory cytokines within the vascular wall. 173 Pro inflammatory cy tokines secreted by macrophages, such as TNF and IL-6, contrib ute to insulin resistance by activating kinases that phosphory late serine residues of IRS-1 and IRS-2 and lead to suppression of metabolic insulin signal ling and promotion of growth factor signalling in the vasculature. 
Adaptive immunity
Accumulating evidence suggest that T-cell activation and dysregulation of T-cell polarization can affect the pathophysiology of hypertension. T helper (T H ) 1 cells mediate the proinflammatory response and oxidative stress, and pro mote infiltration of M1 macrophages into adipose and vas cular tissues. 171 T H 17 cells secrete IL-17, which contributes to vascular injury in hypertension.
174 CD8 + cells that are cytotoxic to the kidney and vasculature in hypertension also secrete IL-17. 112 T regulatory cells (T REG ) are a unique subpopulation of T cells 40 that suppress proinflammatory T-cell responses and promote polarization of M2 macrophages, which in turn leads to an anti-inflammatory response. Insulin resistance and impaired vascular reactivity are associated with depletion of T REG cells and insulin sensitivity can be restored by T REG -cell transfer and/or induction in rodents. 175 T REG cells can also protect against insulin resistance and hypertension via secretion of anti-inflammatory cytokines such as IL-10, which can limit impaired insulin signalling caused by proinflammatory cytokines. 176 Moreover, IL-10 can inhibit NADPH-oxidase-mediated oxidative stress. 177 Finally, in patients with T2DM, an increase in proinflammatory T-cell ratio (that is, elevated levels of T H 17 cells and a decrease in levels of T REG cells might contribute to vascular dysfunction thereby leading to hypertension. 178 Inflammasome Activation of the inflammasome by IL-1β might contribute to insulin resistance, 179 which is a response observed after pathogen exposure or danger-associated signal activation. 180, 181 In obesity states, palmitate and ceramide lipid levels are elevated, which activates inflammasomes. 180 When fed a high-fat diet, mice deficient in central inflammasome molecules fail to become insulin resistant, which is accompanied by suppres sion of immune and inflammatory responses. 180, 181 Mice fed a high-fructose diet become obese and develop hyperuricaemia, which is associated with inflammasome activation, suggesting that uric acid also contributes to an inflammasome response in obesity induced by a high-fructose diet. 182 
RAAS in the immune system
The role of RAAS-mediated immune cell activation in hypertensive states is supported by experiments in Rag1 -/-mice, which have an absolute deficiency of T and B lymphocytes. 183 Adoptive transfer of T cells (but not B cells) can restore normal blood pressure, endothe lial dysfunction, vascular remodelling and reactive oxy gen species production. 183 Moreover, in rats, Ang II trig gers the recruitment of T H 1 cells to renal and cardio vascular tissues, which is prevented by inhibitors of AT 1 R. 40, 112, 171 Adoptive transfer of T REG cells before Ang II infusion can attenuate blood pressure increases and improve vas cular stiffness and impaired vasodilatory responses in young C57BL6 mice. 171 This improvement was associated with attenuation of infiltration of inflammatory monocytes, macro phages, and T H 1 cells, suppression of Ang II-induced NADPH oxidase activity, reactive oxy gen species production, interferon γ (IFN)-γ, TNF, and IL-6 production, and an increase in IL-10 secretion. 177 Similarly, adoptive transfer of T REG cells prevented al dosterone-induced vascular damage in vascular and renal tissues of young C57BL6 mice. 184 RAAS-stimulated activation of the peripheral immune system-via the central nervous system-might also lead to immune-mediated hypertension in patients with obesity. 185, 186 Spleen and lymph nodes are exten sively innervated by the SNS and norepinephrine also modulates T-cell activation. 187, 188 In rats, intra cerebro ventricular administration of Ang II modulates lympho cyte proliferation and spleen cytokine secretion, and sympathetic denervation in the spleen can abolish these effects of Ang II. 189 These studies suggest that the modulation of blood pressure occurs via both peripheral and central immunomodulation in addition to the haemodynam ic effects of RAAS.
Dietary fructose and uric acid
A high-fructose diet can lead to hyperuricaemia owing to decreased renal clearance, increased uric acid production by adipose tissue and increased hepatic production via the induction of fructokinase. 37 Interest ingly, serum uric acid is independently associated with a nondipping circadian pattern of blood pressure in patients with hypertension, 190 and 24-h ambulatory diastolic and daytime systolic blood pressure can be decreased by reducing serum uric acid levels with allopurinol. 191 However, these findings need to be confirmed by large-scale epidemiologic al and interventional studies.
Adipocyte dysfunction, maladaptive immune and inflammatory response, inappropriate activation of RAAS and enhanced oxidative stress all contribute to uricacid-mediated induction of cardiovascular and renal injury. 57, 192 Uric acid increased expression of monocyte chemoattractant protein-1, macrophage infiltration and adipose tissue proinflammatory responses in a murine model of CRS. 193 Uric acid can also contribute to an inflammasome response in obesity induced by a highfructose diet. 192 Uric acid increases AT 1 R levels in the vasculature, thereby contributing to Ang II-mediated endothelial dysfunction and vascular inflammation. 40 Uric acid can also lead to ischaemic renal injury owing to excess collagen deposition, increased macro phage infiltration and expression of osteopontin, 194 elevated juxtaglomerular renin production and reduced NO levels in the macula densa. 194 Ingestion of fructose can also increase salt and water resorption in the small intestine and kidney. Moreover, in rats, a high-fructose diet can induce synthesis of ET-1 leading to hypertension, which can be attenuated by administration of an ET-1 inhibitor. 57, 195 Incretins and DPP-4 Glucagon like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide are gut-derived hormones that enhance glucose-stimulated insulin secretion and suppress glucagon release, thereby modulating postprandial and long-term glucose homeostasis. 196 These incretins are rapidly degraded by the exopeptidase DPP-4, which circulates in the plasma and limits the half-life of these substrate hormones to ~2 min. 196, 197 DPP-4 secretion from adipose tissue and inhibition of insulin-mediated glucose uptake in adipose and muscle cells by DPP-4 suggests that this exopeptidase has direct effects on insu lin resistance (Figure 1) . 198 In the past 10 years, DPP-4-resistant GLP-1 analogues (exenatide and liraglutide) and DPP-4 inhibitors (sitagliptin, vildagliptin, saxigliptin, linagliptin and alogliptin) have been approved in the USA for use in patients with T2DM to lower HbA 1c levels. Augmentation of GLP-1 levels using these drugs can improve cardiovascular outcomes in patients with T2DM, 196, 197 suggesting that their effect extends beyond glycaemic control. Liraglutide and DPP-4 inhibi tors can lower blood pressure in animal models of obe sity and hypertension and in humans with T2DM. 29, 199, 200 Linagliptin also has potent vasodilatory effects in ex vivo vascular ring preparations. 201 DPP-4 substrates other than GLP-1, such as stromal cell derived factor 1α and the natriuretic peptides, 202 might also contribute to the beneficial effect of DPP-4 inhibitors in the vasculature. Natriuretic peptide levels are low in patients with obesity 203 and, therefore, DPP-4 inhibitors might be used to extend the bioavailability of these proteins.
DPP-4 is also widely expressed in the kidney and CD4 + and CD8 + immune cells. 196, 204 DPP-4 inhibitors can reduce the accumulation of M1 macrophages and increase levels of M2 macrophages in adipose tissue or atherosclerotic lesions. 205, 206 Moreover, GLP-1 can enhance T REG -cell function.
207 DPP-4 inhibitors might, therefore, be useful to treat immune-mediated mechanism s of hypertension in obesity.
Estrogen
In premenopausal women, estrogens can lower the risk of CVD; however, this cardioprotective effect is lost in premenopausal women who have obesity and dia betes mellitus. 1, [208] [209] [210] Differences in sympathetic-adrenal ner vous system regulation between men and women sug gest that premenopausal women might have better con trol of stimuli that activate the SNS than men and are consequently protected from development of ar terial hyper tension, which corre lates with results seen in lean hypertensive rats. [211] [212] [213] In these female patients, ar terial stiff ness is substantially higher than in age-matched men, which might explain why obesity limits the cardiovascular protection of estradiol in premenopausal women who have obesity. [214] [215] [216] Estrogen receptor-α and GPR-30 can also increase T REG -cell function, 217 and insulin sensitivity is modulated by signalling mediated by estrogen receptor α in macrophages. 218 Whether these immune functions of T REG cells and macrophages are modulated in premenopausal women who have obesity remains to be determined.
Estrogen modulates Ang II signalling differently under normal and high-salt diets. For example, estradiol suppresses Ang II signalling by reducing AT 1 R expression, 98, 219 whereas GPR-30 increases the expression of angiotensin converting enzyme (ACE) 2, decreas ing AT 1 R expression. 220, 221 By contrast, estradiol can increase AT 1 R expression when NO synthase is inhibited and under high-salt conditions, 222 which suggests that preventing estrogen suppression of Ang II signalling might decrease cardiovascular risk in women who have obesity. In the Framingham study, aldosterone levels were higher in women than in men, and were positively associated with markers of cardiac remodelling, such as left ventricu lar wall thickness in women but not in men. 210 These findings suggest that crosstalk between estro gen and mineralocorticoid receptors might contribute to altered immune and inflammatory responses, endo thelial dys function and arterial stiffness relating to obesity and hypertension in women.
Therapeutics
Lifestyle modifications, including calorie restriction and exercise, are effective in limiting the effect of obesity on hypertension (Figure 2) . However, many patients find weight loss programs difficult to maintain and high dropout rates occur during the initial years of such programs. 223 Pharmacologic interventions are, therefore, useful when patients who have obesity are unable to comply with their weight reduction program or when weight reduction measures alone cannot reduce hy pertension (Figure 2) .
Targeting RAAS can potentially improve multiple pathophysiological components of obesity-associated hypertension, including increasing GLP-1 levels and modulating SGLT2 or SNS overactivation. 29, 38, 223 The angio tensin receptor inhibitor losartan can reduce serum uric acid levels, but a similar effect has not been seen with other such blockers. 224 DPP-4 inhibitors and GLP-1 analogues might also be used to manage hypertension as an add-on therapy in patients with T2DM. 29 Owing to the complex pathophysiology of treatment-resistant hypertension, the correct management of hypertension in patients who have obesity is of major concern to clinicians. 225 Aldosterone antagonists and control of inappropriate SNS activation by renal denervation are emerging as new modalities for the management of treatment-resistant hypertension (Figure 2) . 7, 40, 226 Conclusions Hypertension related to obesity can occur via multiple mechanisms: insulin resistance; adipokine alterations; inappropriate SNS and RAAS activation; structural and functional abnormalities in the kidney, heart and vasculature; and maladaptive immunity. Hyperuricaemia associated with a high-fructose diet also contributes to vascular dysfunction, renal injury and immune activation. DPP-4-mediated incretin signalling can affect vascular function, immune responses and natriuresis in obesity states. Estrogen-mediated insulin sensiti vity in premenopausal women who do not have obesity is compromised when they develop obesity. Alteration in the gut microbiome in obesity is another factor that contributes to insulin resistance and dysfunctional immunity. Treatmentresistant hypertension is more common in individuals with obesity than in those who do not have obesity, especially in patients with OSA, and is a major challenge in the management of hyper tension. Adjunctive therapy with mineralo corticoid receptor antagonists and renal denervation are emerging as therapeutic measures to control treatment-resistant hypertension. Therapeutic strategies targeting obesity-associated hypertension are needed -mineralocorticoid receptor antagonists are especially promising in this context. 7, 29 More studies focused on the clinical utility of treating hypertension in children with obesity are also necessary. Despite the positive therapeutic developments, obesity-related treatment-resistant hy pertension remains a major issue in health care.
Review criteria MEDLINE and PubMed databases were searched for fulltext English-language articles published between 1950 and 2014 with the following terms: "obesity", "resistant hypertension", "insulin resistance", "obstructive sleep apnea", "SNS activation", "high fructose corn syrup", "uric acid", "endothelial dysfunction", "DPP-4", "tissue RAAS", "aldosterone", "adipose dysfunction", "gut microbiome", both alone and in combination. The reference lists of identified articles were also consulted for other relevant papers.
